Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Male or female patients aged \>=18 years~* Patients with Non Valvular Atrial Fibrillation~* Patient presenting with:~An Acute Coronary Syndrome (ACS) (ST elevation myocardial infarction (STEMI), NonSTEMI \[NSTEMI\] or unstable angina \[UA\]) that was successfully treated by PCI and stenting (either Bare Metal Stent (BMS) or Drug Eluting Stent) Or Stable Coronary Artery Disease with at least one lesion eligible for PCI that was successfully treated by elective PCI and stenting (either BMS or DES)~* The patient must be able to give informed consent in accordance with International Conference on Harmonisation Good Clinical Practice guidelines and local legislation and/or regulations.~Exclusion criteria:~* Patients with a mechanical or biological heart valve prosthesis~* Cardiogenic shock during current hospitalisation~* Stroke within 1 month prior to screening visit~* Patients who have had major surgery within the month prior to screening~* Gastrointestinal haemorrhage within one month prior to screening, unless, in the opinion of the Investigator, the cause has been permanently eliminated~* Major bleeding episode including life-threatening bleeding episode in one month prior to screening visit~* Anaemia (haemoglobin \<10g/dL) or thrombocytopenia including heparin-induced thrombocytopenia (platelet count \<100 x 109/L) at screening~* Severe renal impairment (estimated Creatinine Clearance (CrCl) calculated by Cockcroft-Gault equation) \<30mL/min at screening~* Active liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabigatran Etexilate 110mg (Type: EXPERIMENTAL): Patient to receive Dabigatran Etexilate 110mg twice a day (BID)
- Dabigatran Etexilate 150mg (Type: EXPERIMENTAL): Patient to receive Dabigatran Etexilate 150mg twice a day (BID)
- Warfarin (Type: ACTIVE_COMPARATOR): Warfarin doses to maintain INR

Based on this trial design, predict the completion outcome and termination type (if applicable).